The question is gaining traction. Exercise influences HDL cholesterol (the good kind). Diet can influence HDL. And new research shows that some MS drugs do, too:
HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
S Blumenfeld Kan, E Staun-Ram, D Golan, ...
First Published October 14, 2019
https://doi.org/10.1177/2055217319882720
Abstract
Background
Patients with Multiple Sclerosis (PwMS) display altered lipoproteins levels and function, which seem to affect disease risk and progress. Whether disease-modifying therapies affect the lipoprotein profile in PwMS has scarcely been studied.
Objective
The study aims to assess whether fingolimod and dimethyl fumarate (DMF) affect lipoproteins in PwMS.
Methods
We compared retrospectively the blood lipoprotein levels of 29 fingolimod-treated and 41 DMF-treated patients before and after 3 and 12 months of therapy. Patients treated with cholesterol-reducing medications were not included. Data on weight change and disease activity during 1-year follow-up were obtained.
Results
HDL level, HDL/LDL ratio and HDL/total cholesterol ratio were increased in both treatment groups after 3 months’ therapy and sustained, with no change in LDL or triglycerides. While at baseline only 26% of patients met the recommended minimum of HDL 60 mg/dl, after 3 months’ therapy, 43% of fingolimod-treated and 47% of DMF-treated patients reached the recommended level. The majority of patients had no weight reduction.
Conclusions
Fingolimod and DMF therapies are associated with a specific increase in HDL in PwMS. Further studies are required to validate these findings and their potential implication as biomarker of reduced inflammatory state and/or reduced risk of neurodegeneration or cardiovascular comorbidity.
HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
S Blumenfeld Kan, E Staun-Ram, D Golan, ...
First Published October 14, 2019
https://doi.org/10.1177/2055217319882720
Abstract
Background
Patients with Multiple Sclerosis (PwMS) display altered lipoproteins levels and function, which seem to affect disease risk and progress. Whether disease-modifying therapies affect the lipoprotein profile in PwMS has scarcely been studied.
Objective
The study aims to assess whether fingolimod and dimethyl fumarate (DMF) affect lipoproteins in PwMS.
Methods
We compared retrospectively the blood lipoprotein levels of 29 fingolimod-treated and 41 DMF-treated patients before and after 3 and 12 months of therapy. Patients treated with cholesterol-reducing medications were not included. Data on weight change and disease activity during 1-year follow-up were obtained.
Results
HDL level, HDL/LDL ratio and HDL/total cholesterol ratio were increased in both treatment groups after 3 months’ therapy and sustained, with no change in LDL or triglycerides. While at baseline only 26% of patients met the recommended minimum of HDL 60 mg/dl, after 3 months’ therapy, 43% of fingolimod-treated and 47% of DMF-treated patients reached the recommended level. The majority of patients had no weight reduction.
Conclusions
Fingolimod and DMF therapies are associated with a specific increase in HDL in PwMS. Further studies are required to validate these findings and their potential implication as biomarker of reduced inflammatory state and/or reduced risk of neurodegeneration or cardiovascular comorbidity.
Comment